Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + temozolomide + surufatinib
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This investigational combination therapy consists of sintilimab, surufatinib, and temozolomide, currently being evaluated in a Phase II clinical trial for the treatment of advanced neuroendocrine carcinoma (NEC). Sintilimab is a fully human IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to restore T-cell antitumor activity. Surufatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits VEGFR-1, -2, and -3, FGFR1, and CSF-1R, thereby inhibiting tumor angiogenesis and modulating the tumor immune microenvironment by reducing tumor-associated macrophages. Temozolomide is an oral alkylating agent that exerts its cytotoxic effect by methylating DNA, primarily at the O6 and N7 positions of guanine, leading to DNA damage and apoptosis. The combination aims to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy in patients who have progressed on first-line treatments.
- Other names
- Sintilimab+Temozolomide+SurufatinibSintilimab, Surufatinib, and Temozolomide in Advanced Neuroendocrine Carcinoma
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on sintilimab + temozolomide + surufatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + temozolomide + surufatinib.